Charles River Laboratories International, Inc. – NYSE:CRL
Charles River Laboratories International stock price today
$158.6
-27.56
-14.8%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Charles River Laboratories International stock price monthly change
-13.89%
month
Charles River Laboratories International stock price quarterly change
-13.89%
quarter
Charles River Laboratories International stock price yearly change
-22.06%
year
Charles River Laboratories International key metrics
Market Cap | 9.50B |
Enterprise value | 13.16B |
P/E | 21.28 |
EV/Sales | 3.31 |
EV/EBITDA | 13.43 |
Price/Sales | 2.59 |
Price/Book | 3.46 |
PEG ratio | 0.91 |
EPS | 8.66 |
Revenue | 4.11B |
EBITDA | 1.01B |
Income | 438.82M |
Revenue Q/Q | -1.73% |
Revenue Y/Y | 0.49% |
Profit margin | 12.23% |
Oper. margin | 16.37% |
Gross margin | 36.79% |
EBIT margin | 16.37% |
EBITDA margin | 24.76% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCharles River Laboratories International stock price history
Charles River Laboratories International stock forecast
Charles River Laboratories International financial statements
Average Price Target
$201.5
Potential upside: 27.04%
Analysts Price target
Financials & Ratios estimates
| Jul 2023 | 1.05B | 97.02M | 9.15% |
|---|---|---|---|
| Sep 2023 | 1.02B | 87.38M | 8.51% |
| Dec 2023 | 1.01B | 187.08M | 18.46% |
| Mar 2024 | 1.01B | 67.32M | 6.66% |
| Jul 2023 | 7772381000 | 4.47B | 57.54% |
|---|---|---|---|
| Sep 2023 | 7607007000 | 4.25B | 55.95% |
| Dec 2023 | 8195001000 | 4.53B | 55.35% |
| Mar 2024 | 8152783000 | 4.44B | 54.57% |
| Jul 2023 | 148.12M | -76.60M | -71.46M |
|---|---|---|---|
| Sep 2023 | 205.45M | -79.55M | -162.86M |
| Dec 2023 | 220.94M | -238.37M | 123.56M |
| Mar 2024 | 129.88M | -85.79M | 18.34M |
Charles River Laboratories International alternative data
Charles River Laboratories International Social Media Accounts
What are followers?
+0.41%
month
| May 2025 | 5294 |
|---|---|
| Jul 2025 | 5352 |
| Aug 2025 | 5374 |
Charles River Products and Services
| 12 Feb 2023 | 0 | 48 |
|---|---|---|
| 19 Feb 2023 | 0 | 51 |
| 26 Feb 2023 | 0 | 57 |
| 5 Mar 2023 | 0 | 67 |
| 12 Mar 2023 | 1 | 61 |
| 19 Mar 2023 | 1 | 68 |
| 26 Mar 2023 | 1 | 67 |
| 2 Apr 2023 | 0 | 62 |
| 9 Apr 2023 | 0 | 57 |
| 16 Apr 2023 | 0 | 49 |
| 23 Apr 2023 | 0 | 48 |
| 30 Apr 2023 | 0 | 41 |
| 7 May 2023 | 0 | 49 |
| 14 May 2023 | 0 | 49 |
| 21 May 2023 | 0 | 52 |
| 28 May 2023 | 0 | 51 |
| 4 Jun 2023 | 1 | 49 |
| 11 Jun 2023 | 0 | 47 |
| 18 Jun 2023 | 0 | 44 |
| 25 Jun 2023 | 0 | 50 |
Numbers represent search interest relative to the highest point on the chart for the given region and time.
A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.
What is job openings count?
| Aug 2023 | 359 |
|---|---|
| Sep 2023 | 378 |
| Oct 2023 | 372 |
| Nov 2023 | 385 |
| Dec 2023 | 346 |
| Jan 2024 | 327 |
| Feb 2024 | 322 |
| Apr 2024 | 307 |
| May 2024 | 369 |
| Jun 2024 | 356 |
| Jul 2024 | 351 |
| Dec 2024 | 252 |
| Aug 2023 | 20,000 |
|---|---|
| Sep 2023 | 20,000 |
| Oct 2023 | 20,000 |
| Nov 2023 | 20,000 |
| Dec 2023 | 20,000 |
| Jan 2024 | 20,000 |
| Feb 2024 | 20,000 |
| Mar 2024 | 20,400 |
| Apr 2024 | 20,400 |
| May 2024 | 20,400 |
| Jun 2024 | 20,400 |
| Jul 2024 | 20,400 |
Charles River Laboratories International other data
94.03%
+2.45%
of CRL is owned by hedge funds
611
-14
48.22M
+1.21M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2023 | 1000 | 7934 |
| Nov 2023 | 6942 | 10978 |
| Dec 2023 | 0 | 5526 |
| Feb 2024 | 0 | 19556 |
| Mar 2024 | 0 | 3558 |
| May 2024 | 0 | 1636 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | MASSARO GEORGE director | Common Stock | 123 | $234.72 | $28,871 | ||
Sale | MASSARO GEORGE director | Common Stock | 113 | $235.61 | $26,624 | ||
Sale | MASSARO GEORGE director | Common Stock | 96 | $236.78 | $22,731 | ||
Sale | LAPLUME JOSEPH W officer: EVP, Cor.. | Common Stock | 1,304 | $226.97 | $295,969 | ||
Sale | KNELL MICHAEL GUNNAR officer: CSVP&Chief Accounting .. | Common Stock | 808 | $267.52 | $216,156 | ||
Sale | KNELL MICHAEL GUNNAR officer: CSVP&Chief Accounting .. | Common Stock | 1,750 | $260.88 | $456,540 | ||
Sale | KNELL MICHAEL GUNNAR officer: CSVP&Chief Accounting .. | Common Stock | 1,000 | $261.35 | $261,350 | ||
Sale | PARISOTTO SHANNON M officer: CEVP, Disc & Safety As.. | Common Stock | 100 | $254.02 | $25,402 | ||
Sale | PARISOTTO SHANNON M officer: CEVP, Disc & Safety As.. | Common Stock | 3,686 | $253.43 | $934,143 | ||
Sale | CREAMER VICTORIA L officer: EVP & Chief People Off.. | Common Stock | 5,000 | $253.7 | $1,268,500 |
| Patent |
|---|
Application Filling date: 26 Apr 2022 Issue date: 11 Aug 2022 |
Application Filling date: 31 Jan 2022 Issue date: 19 May 2022 |
Grant Utility: CHO host cell protein assay Filling date: 18 Sep 2018 Issue date: 8 Mar 2022 |
Application Filling date: 5 Mar 2021 Issue date: 24 Jun 2021 |
Application Filling date: 18 Feb 2021 Issue date: 24 Jun 2021 |
Grant Filling date: 1 Jun 2016 Issue date: 23 Mar 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2023 11 May 2023 | Q1 2023 Earnings Call Transcript |
| Q4 2022 22 Feb 2023 | Q4 2022 Earnings Call Transcript |
| Q3 2022 2 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 3 Aug 2022 | Q2 2022 Earnings Call Transcript |
Fortrea: Turning Around As The Activists Move In
ICON: A High Probability Of Success In The Uncertain R&D Process
Medpace: Clear Winner If China Blockade Succeeds
Charles River Laboratories: Fair Valuation Against Fundamentals
Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation
Charles River Laboratories: Diving Into The Lab (Rating Upgrade)
Charles River Laboratories: Very Attractive After The Pullback
Charles River: Strong Earnings Manifest Life Science Megatrends
Syneos Health: Rumors Of Private Equity Circling, Potential 40% Upside
-
What's the price of Charles River Laboratories International stock today?
One share of Charles River Laboratories International stock can currently be purchased for approximately $158.6.
-
When is Charles River Laboratories International's next earnings date?
Unfortunately, Charles River Laboratories International's (CRL) next earnings date is currently unknown.
-
Does Charles River Laboratories International pay dividends?
No, Charles River Laboratories International does not pay dividends.
-
How much money does Charles River Laboratories International make?
Charles River Laboratories International has a market capitalization of 9.50B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 3.86% to 4.13B US dollars.
-
What is Charles River Laboratories International's stock symbol?
Charles River Laboratories International, Inc. is traded on the NYSE under the ticker symbol "CRL".
-
What is Charles River Laboratories International's primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of Charles River Laboratories International?
Shares of Charles River Laboratories International can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Charles River Laboratories International's key executives?
Charles River Laboratories International's management team includes the following people:
- Mr. James C. Foster Chairman, Chief Executive Officer & Pres(age: 74, pay: $3,070,000)
- Mr. David Ross Smith Corporation Executive Vice President & Chief Financial Officer(age: 59, pay: $1,180,000)
- Mr. William D. Barbo Chief Commercial Officer & Corporation Executive Vice President(age: 64, pay: $994,680)
- Mr. Joseph W. LaPlume Corporation Executive Vice President of Corporation Devel. & Strategy(age: 51, pay: $941,780)
- Ms. Birgit Girshick Corporation Executive Vice President & Chief Operating Officer(age: 55, pay: $912,920)
-
How many employees does Charles River Laboratories International have?
As Jul 2024, Charles River Laboratories International employs 20,400 workers.
-
When Charles River Laboratories International went public?
Charles River Laboratories International, Inc. is publicly traded company for more then 25 years since IPO on 23 Jun 2000.
-
What is Charles River Laboratories International's official website?
The official website for Charles River Laboratories International is criver.com.
-
Where are Charles River Laboratories International's headquarters?
Charles River Laboratories International is headquartered at 251 Ballardvale Street, Wilmington, MA.
-
How can i contact Charles River Laboratories International?
Charles River Laboratories International's mailing address is 251 Ballardvale Street, Wilmington, MA and company can be reached via phone at +7 812226000.
-
What is Charles River Laboratories International stock forecast & price target?
Based on 4 Wall Street analysts` predicted price targets for Charles River Laboratories International in the last 12 months, the avarage price target is $201.5. The average price target represents a 27.04% change from the last price of $158.6.
Charles River Laboratories International company profile:
Charles River Laboratories International, Inc.
criver.comExchange:
NYSE
Full time employees:
20,400
Industry:
Medical - Diagnostics & Research
Sector:
Healthcare
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
251 Ballardvale Street
Wilmington, MA 01887
Wilmington, MA 01887
CIK: 0001100682
ISIN: US1598641074
CUSIP: 159864107
